Trans-3,5,4 ́-trimethoxystilbene (TMS) also reduces NSCLC resistance to gefitinib by upregulating miR-345 and miR-498, which inhibits the MAPK/AKT/Bcl-2 pathway [21]. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.